Bristol Myers Squibb (BMY): Q1 2026 Earnings Preview and What to Watch
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $10.93 billion, a roughly 2.5% decline year-over-year.
- Consensus adjusted EPS (earnings per share) is forecasted at $1.44-$1.46, reflecting ongoing transition dynamics.
- Growth Portfolio, including key immuno-oncology drugs like Opdivo, is anticipated to show continued momentum offsetting legacy product declines.
- Company reaffirmed 2026 guidance for revenue of $46-$47.5 billion and adjusted EPS of $6.05-$6.35.
- Q4 2025 revenue hit $12.5 billion, up 1% YoY, with Growth Portfolio surging 16% to $7.4 billion.
- Investors watching for updates on pipeline progress and Eliquis demand amid patent challenges.
Earnings Context and Why It Matters
As Bristol Myers Squibb's Q1 2026 earnings, due on April 30, 2026, draw near, this report feels particularly pivotal. The company is in the midst of a strategic shift, with its Growth Portfolio now accounting for nearly 60% of sales. Legacy blockbusters like Revlimid are dealing with post-patent erosion, but newer assets in oncology and immunology are stepping up to offset those declines. Recent quarters demonstrate resilience—Q4 2025 saw Growth Portfolio growth of 16%—yet overall revenue faces ongoing pressures from industry pricing and competition. For investors like myself, this earnings release provides key insights into execution against 2026 guidance and potential pipeline catalysts, which could influence BMY's valuation in a sector that rewards sustainable innovation.
Earnings Expectations
Wall Street's projections point to Q1 revenue of $10.92-$10.94 billion, down about 2.5% from last year, as legacy declines are partially tempered by Growth Portfolio gains. The consensus for adjusted EPS lands at $1.44-$1.46, which could mark a year-over-year drop influenced by margin pressures and R&D investments. I'm particularly focused on metrics like Growth Portfolio performance, Eliquis volumes, and Opdivo market share. BMY has a track record of beating revenue estimates lately, as seen in Q4 2025's $12.5 billion against expectations. Post-earnings stock moves have been mixed, averaging a slight -0.1%, with upside typically tied to strong guidance reaffirmations.
Market Reaction and Investor Sentiment
Sentiment heading into these Q1 results strikes me as cautiously optimistic, supported by the Q4 beats and positive 2026 guidance, even with the anticipated revenue dip. Options pricing suggests a ~4-5% stock move after the report, in line with historical volatility. Shares climbed after the recent Q4 despite legacy softness, indicating the market's emphasis on the growth trajectory. That said, risks loom, such as potential guidance cuts or underwhelming pipeline updates in a competitive oncology environment.
Tools I Use: Tickeron’s AI Screener
One tool I turn to regularly when analyzing stocks like BMY is Tickeron’s AI Screener, an AI-powered platform for discovering stocks and ETFs. It lets me filter thousands of names using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI-driven signals—far more efficiently than manual screening. Whether spotting trade ideas, breakout candidates, or industry comparables, it streamlines my process and highlights opportunities I might otherwise miss. If you're looking to deepen your market scans, it's worth exploring.
Forward Outlook and Key Factors to Monitor
Post-Q1, I'll be watching closely for reaffirmation of the 2026 guidance: revenue of $46-47.5 billion and adjusted EPS of $6.05-$6.35, driven by Growth Portfolio expansion toward over 60% of sales. From what I see, pipeline milestones—like Opdivo combinations and launches such as Cobenfy (KarXT)—will be crucial, especially amid Eliquis pricing pressures and patent cliffs. Cost discipline in R&D and manufacturing could help margins hold up. I also checked BMY's trends using Tickeron’s AI Trend Prediction Engine to gauge momentum.
Broader dynamics, including biosimilar competition and M&A activity, deserve attention too. Key upcoming catalysts involve mid-year data readouts and regulatory decisions that could shape long-term demand.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
BMY in downward trend: price dove below 50-day moving average on September 16, 2026
BMY moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend. In 29 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BMY moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 16 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In 50 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 22 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 172 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 201 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.770) is normal, around the industry mean (19.050). P/E Ratio (13.890) is within average values for comparable stocks, (34.258). BMY's Projected Growth (PEG Ratio) (17.558) is slightly higher than the industry average of (5.614). Dividend Yield (0.040) settles around the average of (0.025) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor
Advertisement